Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
about
Concentrated insulins: the new basal insulinsInsulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectivesrDNA insulin glargine U300 - a critical appraisalPharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance MeasuresInsulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.The past, present, and future of basal insulins.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of DiabetesComparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Understanding concentrated insulins: a systematic review of randomized controlled trials.Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.High Concentration Insulin.Advances in Basal Insulin Therapy.U300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes.
P2860
Q26750438-4D171D23-E5DA-4EEB-90A6-2479562FAE09Q28074690-E5CFCE0B-8ADD-487B-ABA9-B7589A04AD54Q28077366-C044764B-00FB-4C13-B5C5-9F6CE0A6D32DQ30244827-2480363A-E0AE-4E63-9606-DA5C551F439CQ30248803-9C6F0408-3270-4575-8BB0-549BC5DB07A7Q30978373-4F46024B-B598-4072-8516-C03ED2AFAC8DQ33727441-A9E473B2-2BAE-4620-B9A9-D80984B36132Q33884391-21A7CDEF-FC5B-4641-91B5-A7D02E756013Q35772552-C2F46A69-CF00-4C8E-B42E-326C9053423FQ36467597-5DB3D358-1542-4F47-B436-CAA1E3366BFBQ37343841-E93AA7CF-03D0-42CA-9221-E5F051FAA3A0Q38386958-65DF529C-A9E9-4680-9EAB-5F35AAA50DBFQ38559945-D969A5EC-C12A-413D-A38D-B24FAFE9FD89Q38570757-51D81682-1A2E-4F4C-B796-9AF28FF626C8Q38618376-2AE2F873-1837-4556-9BD5-350C21086859Q38692387-6777DABA-852B-4B58-B477-5572B6813071Q38715053-CDE2F3F7-5EEC-4333-8BCB-3A9B76520299Q38811608-FFBADA8E-6F61-4181-BCD0-C606FF21A46FQ38858785-F014BCF7-3F03-414D-925D-CE10547DD68AQ38871135-C75CE7F9-4B38-47BF-9E4D-09D8F54609F3Q38971612-5AEE06A4-5573-4498-BD9C-F5D262329925Q39093052-59A2679F-C0E0-407E-9B79-5067B42EE1BBQ46199321-67BAE77A-F99F-4BFE-9AAD-FEB8F462DDB7Q47322851-E45151FC-CC25-432F-AD79-88D30A5545B5Q47684311-0D77DDDE-B6A5-476F-B2C0-84EBB67CCEA7Q48088343-15AE5D69-1580-4731-B512-EA048E72970EQ53449720-6CE8A2C1-0063-40F3-8C7F-E6F7F99C4F0AQ55007996-3F4D207B-FF8A-41FA-A0AC-7DEDDC11D03DQ55309585-632A1BF3-0E25-4EAA-8E35-11A4A068FD7EQ55402139-B43D3BDA-75A5-4B99-9E19-E38B4EA255B7
P2860
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@ast
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@en
type
label
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@ast
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@en
prefLabel
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@ast
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@en
P2093
P2860
P356
P1476
Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
@en
P2093
K Bergmann
L Teichert
R H A Becker
P2860
P304
P356
10.1111/DOM.12416
P577
2015-01-07T00:00:00Z